169 related articles for article (PubMed ID: 22554766)
1. Tumor-type-dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin.
Abu Lila AS; Matsumoto H; Doi Y; Nakamura H; Ishida T; Kiwada H
Eur J Pharm Biopharm; 2012 Aug; 81(3):524-31. PubMed ID: 22554766
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model.
Abu Lila AS; Kizuki S; Doi Y; Suzuki T; Ishida T; Kiwada H
J Control Release; 2009 Jul; 137(1):8-14. PubMed ID: 19285528
[TBL] [Abstract][Full Text] [Related]
3. Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: importance of vascular permeability within tumors.
Ogawara K; Un K; Minato K; Tanaka K; Higaki K; Kimura T
Int J Pharm; 2008 Jul; 359(1-2):234-40. PubMed ID: 18448289
[TBL] [Abstract][Full Text] [Related]
4. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome.
Suzuki R; Takizawa T; Kuwata Y; Mutoh M; Ishiguro N; Utoguchi N; Shinohara A; Eriguchi M; Yanagie H; Maruyama K
Int J Pharm; 2008 Jan; 346(1-2):143-50. PubMed ID: 17640835
[TBL] [Abstract][Full Text] [Related]
5. Liposomal quercetin efficiently suppresses growth of solid tumors in murine models.
Yuan ZP; Chen LJ; Fan LY; Tang MH; Yang GL; Yang HS; Du XB; Wang GQ; Yao WX; Zhao QM; Ye B; Wang R; Diao P; Zhang W; Wu HB; Zhao X; Wei YQ
Clin Cancer Res; 2006 May; 12(10):3193-9. PubMed ID: 16707620
[TBL] [Abstract][Full Text] [Related]
6. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH
Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model.
Abu-Lila A; Suzuki T; Doi Y; Ishida T; Kiwada H
J Control Release; 2009 Feb; 134(1):18-25. PubMed ID: 19010364
[TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice.
Newman MS; Colbern GT; Working PK; Engbers C; Amantea MA
Cancer Chemother Pharmacol; 1999; 43(1):1-7. PubMed ID: 9923534
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin encapsulated in phosphatidylethanolamine liposomes enhances the in vitro cytotoxicity and in vivo intratumor drug accumulation against melanomas.
Hwang TL; Lee WR; Hua SC; Fang JY
J Dermatol Sci; 2007 Apr; 46(1):11-20. PubMed ID: 17267180
[TBL] [Abstract][Full Text] [Related]
10. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
[TBL] [Abstract][Full Text] [Related]
11. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.
Ogawara K; Un K; Tanaka K; Higaki K; Kimura T
J Control Release; 2009 Jan; 133(1):4-10. PubMed ID: 18840484
[TBL] [Abstract][Full Text] [Related]
12. Sterically stabilized anti-G(M3), anti-Le(x) immunoliposomes: targeting to B16BL6, HRT-18 cancer cells.
Nam SM; Kim HS; Ahn WS; Park YS
Oncol Res; 1999; 11(1):9-16. PubMed ID: 10451027
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model.
Doi Y; Okada T; Matsumoto H; Ichihara M; Ishida T; Kiwada H
Cancer Sci; 2010 Nov; 101(11):2470-5. PubMed ID: 20731663
[TBL] [Abstract][Full Text] [Related]
14. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes.
Harasym TO; Cullis PR; Bally MB
Cancer Chemother Pharmacol; 1997; 40(4):309-17. PubMed ID: 9225948
[TBL] [Abstract][Full Text] [Related]
15. Oxystress inducing antitumor therapeutics via tumor-targeted delivery of PEG-conjugated D-amino acid oxidase.
Fang J; Deng D; Nakamura H; Akuta T; Qin H; Iyer AK; Greish K; Maeda H
Int J Cancer; 2008 Mar; 122(5):1135-44. PubMed ID: 17990314
[TBL] [Abstract][Full Text] [Related]
16. Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT).
Maruyama K; Ishida O; Kasaoka S; Takizawa T; Utoguchi N; Shinohara A; Chiba M; Kobayashi H; Eriguchi M; Yanagie H
J Control Release; 2004 Aug; 98(2):195-207. PubMed ID: 15262412
[TBL] [Abstract][Full Text] [Related]
17. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
[TBL] [Abstract][Full Text] [Related]
18. In vivo antitumor activity of cis-bis-neodecanoato-trans-R,R-1, 2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes.
Mori A; Wu SP; Han I; Khokhar AR; Perez-Soler R; Huang L
Cancer Chemother Pharmacol; 1996; 37(5):435-44. PubMed ID: 8599866
[TBL] [Abstract][Full Text] [Related]
19. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system.
Rice JR; Gerberich JL; Nowotnik DP; Howell SB
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2248-54. PubMed ID: 16609041
[TBL] [Abstract][Full Text] [Related]
20. Optimization of (1,2-diamino-cyclohexane)platinum(II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity.
Cabral H; Nishiyama N; Kataoka K
J Control Release; 2007 Aug; 121(3):146-55. PubMed ID: 17628162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
